Latest News

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
05/26/16AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 following Ambulatory Abdominal Surgeries at Euroanaesthesia
REDWOOD CITY, Calif., May 26, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at Euroanaesthesia 2016, which is taking place in London, UK on May 28-30, 2016. In the SAP301 study, patients with moderate-to-severe acute pain following abdominoplasty, hernioplasty or laparoscopic abdominal surgeries were randomized to receive either ARX-04 (sufentanil sublingual 30 mcg tablet) or... 
Printer Friendly Version
05/24/16New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140
Results to be Presented at the 21st ISPOR Annual International Meeting REDWOOD CITY, Calif., May 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department for the treatment of acute pain. Based on an analysis of over 7 million patients who received IV opioids in 614 US emergency departments, it was found that the cost of administering an initial IV opioi... 
Printer Friendly Version
05/06/16AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX‑04 by Type of Abdominal Surgery
REDWOOD CITY, Calif., May 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting a subgroup analysis of the Phase 3 SAP301 study results by surgery type (abdominoplasty, hernioplasty and laparoscopic abdominal surgery). SAP301 was a Phase 3 trial comparing ARX-04 (sufentanil sublingual 30 mcg tablet) to a placebo sublingual tablet in 163 patients with moderate-to-severe acute pain following ambulatory abdomina... 
Printer Friendly Version
05/04/16AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in May
REDWOOD CITY, Calif., May 4, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at BioEquity Europe Conference 2016 and Bank of America Merrill Lynch 2016 Health Care Conference. BioEquity Europe Conference 2016 Date: Wednesday, May 11 Location: Scandic Hotel, Copenhagen Presenta... 
Printer Friendly Version
05/02/16AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results
REDWOOD CITY, Calif., May 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three months ended March 31, 2016.     Corporate Highlights ARX-04 Emergency Room and Postoperative Studies: AcelRx initiated two Phase 3 studies in the first quarter of 201... 
Printer Friendly Version
04/28/16AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 2nd, 2016
REDWOOD CITY, Calif., April 28, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release First Quarter financial results after market close on Monday, May 2nd, 2016. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 2nd, 2016 to discuss t... 
Printer Friendly Version
03/29/16AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
Conference call update at 4:30pm ET today REDWOOD CITY, Calif., March 29, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015.  Mr. Ro... 
Printer Friendly Version
03/25/16AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and Pharmacoeconomics
- Zalviso Clinical Program Highlighted in Publication in Hospital Pharmacy - REDWOOD CITY, Calif., March 25, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported that a review article entitled "Evolution of Patient-Controlled Analgesia: From Intravenous to Sublingual Treatment" has been published in the peer-revie... 
Printer Friendly Version
03/14/16AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
REDWOOD CITY, Calif., March 14, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced the initiation of the extension phase of the SAP302 study of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. This ongoing open-label P... 
Printer Friendly Version
03/07/16AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results
REDWOOD CITY, Calif., March 7, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three and twelve months ended December 31, 2015.     Corporate Update and 2016 Objectives ARX-04 ER and Postoperative Studies: In December 2015, AcelRx, along with represen... 
Printer Friendly Version
03/07/16AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif., March 7, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today that patient enrollment and dosing in a multicenter, open-label Phase 3 clinical study, known as SAP303, has been initiated. SAP303 is being conducted in patients 40 years and older who have moderate-to-severe acute pain follow... 
Printer Friendly Version
03/03/16AcelRx Pharmaceuticals to Hold Annual 2015 Financial Results Conference Call and Webcast on Monday, March 7th, 2016.
REDWOOD CITY, Calif., March 3, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that it will release fourth quarter and yearly 2015 financial results after market close on Monday, March 7th, 2016. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 7... 
Printer Friendly Version
03/01/16AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in March
REDWOOD CITY, Calif., March 1, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at the 36th Annual Health Care Conference in Boston and the 28th Annual ROTH Conference in Orange County. Details of the conferences are as follows: 36th Annual Health Care Conference Date:  Wednesday... 
Printer Friendly Version
02/25/16AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis
REDWOOD CITY, Calif., Feb. 25, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today reported encouraging interim efficacy and safety results of the ongoing single-arm, open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain asso... 
Printer Friendly Version
02/11/16AcelRx Pharmaceuticals Presents Phase 3 Results from ARX-04 Clinical Program at JAB Burn and Wound Care Symposium
REDWOOD CITY, Calif., Feb. 11, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a podium presentation will be made at the 38th annual John A. Boswick, M.D. Burn and Wound Care Symposium, which is being held February 14-18, 2016 in Hawaii. This international conference covers the latest advancements in wound healing, burn care, and infection control, and is endorsed by the American Burn Association, Australian-New Zealand Burns Association, Academy of Physicia... 
Printer Friendly Version
02/03/16AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February
REDWOOD CITY, Calif., Feb. 3, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer and Head of Business Development, Timothy E. Morris will be presenting at the 18th Annual BIO CEO & Investor Conference and the 2016 RBC Capital Markets' Healthcare Conference in New York. Details of the conference... 
Printer Friendly Version
01/21/16AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery
Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations REDWOOD CITY, Calif., Jan. 21, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made at the annual European Congress of Ambulatory Surgery to be held January 28th and 29th, 2016 at the Disneyland Hotel New York Convention Centre in Paris, France.  This bilingual congress (simultaneous translation will be provided)... 
Printer Friendly Version
01/10/16AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones
- ARX-04 ER and Postoperative Study Results, NDA Submission - Initiation and Completion of Final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission - Zalviso™ Commercial Launch in the European Union REDWOOD CITY, Calif., Jan. 10, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced anticipated 2016 milestones for i... 
Printer Friendly Version
01/08/16AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso™ in 1Q 2016
REDWOOD CITY, Calif., Jan. 8, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported that the Company has received comments from the Division of Anesthesia, Analgesia, and Addiction Products (Division) of the U.S. Food and Drug Administration (FDA) on the Company's proposed protocol for a Phase 3 clinical study (IAP312) d... 
Printer Friendly Version